Long-term results of treatment of patients with type 2 diabetes with sodium-glucose cotransporter-2 (sglt2) inhibitors
Kravchun N.O., Zemlyanitsyna O.V., Dunaeva I.P., Dorosh O.G.
Sodium-glucose cotransporter-2 (SGLT2) inhibitors are medications that protect against cardiovascular diseases and mortality in patients with diabetes mellitus (DM) type 2 of different age groups with the presence of comorbid pathology and numerous complications. Huge data of results achieved may vary in different cases, but already existing data testify the importance and necessity of prescribing such innovative medications as SGLT2. The aim of the study. Tracking the long-term results of the combined therapy of dapagliflozin and metformin on the state of carbohydrate, lipid and protein metabolism, indicators of liver function in patients with type 2 diabetes, representatives of the Ukrainian population.
Materials and methods: 60 patients with type 2 diabetes took part in the study, 34 of them were men and 26 — women. The average age of the patients was (57.52 ± 0.96) years. 39 (65.0%) patients had diabetes of moderate severity, hundred, in 21 (35.0%) – of severe diabetes. Insulin dependence was observed in 11 patients (18.3%). Therapy of patients with type 2 diabetes included adherence to dietary recommendations, namely, nutritional correction and prescription of tableted oral hypoglycemic agents: dpagliflozin in a daily dose 10 mg and metformin in a daily dose of 1,500 to 2,000 mg, in 11 patients along with tableted sugar-lowering insulin was additionally prescribed as a general medication. Levels were determined for all patients of carbohydrate, lipid and protein metabolism, indicators of liver function.
The results. Long-term treatment with dapagliflozin in combination with metformin in patients with type 2 diabetes showed its effectiveness. An improvement in the indicators of carbohydrate, lipid and protein metabolism was found, indicators of liver tests and liver synthetic function in patients with type 2 diabetes, representatives of Ukrainian population.
Conclusions. The expediency of using the combination of dapagliflozin in combination with with metformin as hypoglycemic therapy for a long period in patients with type 2 diabetes.
Keywords: type 2 diabetes, Sodium-glucose cotransporter-2 (SGLT2) inhibitors, treatment